Valuation: PREDILIFE

Market Cap 3.75M 4.27M 3.48M 3.2M 6.01M 412M 6.11M 41.6M 16.23M 202M 16.01M 15.66M 699M P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 8.53M 9.7M 7.92M 7.28M 13.66M 937M 13.9M 94.61M 36.92M 459M 36.41M 35.62M 1.59B EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 day-9.52%
1 week-47.37%
Current month-58.70%
1 month-60.42%
3 months-69.35%
6 months-71.30%
Current year-68.44%
1 week 0.95
Extreme 0.95
1.44
1 month 0.95
Extreme 0.95
2.57
Current year 0.95
Extreme 0.95
4
1 year 0.95
Extreme 0.95
4
3 years 0.95
Extreme 0.95
24
5 years 0.95
Extreme 0.95
24
10 years 0.95
Extreme 0.95
24
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2004
Chief Tech/Sci/R&D Officer - 01/01/2007
General Counsel - 01/01/2016
Director TitleAgeSince
Chairman 56 01/01/2004
Director/Board Member 46 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
27/7/23 Buy

Chief Executive Officer

1,200 0.0328%
23/3/22 Sell

Chief Executive Officer

3,000 0.0820%
9/3/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
-9.52%-47.37%-73.46%-84.17% 4.73M
-0.22%-2.74%+146.19%+102.52% 4.63B
+1.64%-2.58%+111.87%+176.11% 3.51B
-0.77%+8.23%+63.90%-33.12% 2.31B
-1.76%-1.45%-27.07%-36.48% 2.13B
-0.45%+26.42%+188.86%+253.81% 1.95B
-0.70%+0.14%+178.66%-43.60% 1.05B
+2.42%-5.81%-8.77%+28.14% 830M
+0.67%-1.89%-36.38%-13.58% 494M
+6.72%-12.13%-7.56% - 407M
Average -0.20%-2.51%+53.62%+38.85% 1.73B
Weighted average by Cap. +0.15%+2.60%+97.44%+83.14%

Financials

2024 2025
Net sales 493K 561K 458K 421K 790K 54.2M 804K 5.47M 2.14M 26.54M 2.11M 2.06M 91.9M 836K 951K 776K 714K 1.34M 91.85M 1.36M 9.27M 3.62M 44.97M 3.57M 3.49M 156M
Net income -4.26M -4.85M -3.96M -3.64M -6.83M -469M -6.95M -47.32M -18.47M -229M -18.21M -17.82M -795M -3.93M -4.48M -3.66M -3.36M -6.3M -432M -6.42M -43.66M -17.04M -212M -16.8M -16.44M -733M
Net Debt 3.54M 4.03M 3.29M 3.02M 5.67M 389M 5.77M 39.26M 15.32M 190M 15.11M 14.78M 659M 4.78M 5.44M 4.44M 4.08M 7.65M 525M 7.79M 53.01M 20.69M 257M 20.4M 19.96M 890M
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
23/07/26 EUR 0.9500 -9.52% 1,836
22/07/26 EUR 1.050 -8.70% 1,317
21/07/26 EUR 1.150 -10.85% 999
20/07/26 EUR 1.290 -0.77% 4,228
17/07/26 EUR 1.300 -13.33% 1,144

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALPRE Stock